Norinchukin Bank The Has $5.49 Million Position in Stryker Co. (NYSE:SYK)

Norinchukin Bank The raised its holdings in Stryker Co. (NYSE:SYK - Free Report) by 8.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,260 shares of the medical technology company's stock after acquiring an additional 1,228 shares during the quarter. Norinchukin Bank The's holdings in Stryker were worth $5,494,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in SYK. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Stryker during the 4th quarter worth $25,000. Rakuten Securities Inc. grew its position in Stryker by 618.2% in the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock worth $28,000 after purchasing an additional 68 shares during the last quarter. Centricity Wealth Management LLC bought a new stake in shares of Stryker in the fourth quarter valued at about $30,000. BankPlus Trust Department bought a new stake in shares of Stryker in the 4th quarter worth approximately $33,000. Finally, Activest Wealth Management acquired a new stake in Stryker during the fourth quarter worth $36,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on SYK. Stifel Nicolaus increased their price target on shares of Stryker from $400.00 to $440.00 and gave the stock a "buy" rating in a research report on Wednesday, January 29th. Citigroup reissued a "buy" rating and issued a $450.00 target price on shares of Stryker in a report on Wednesday, February 26th. Argus set a $450.00 price target on Stryker in a research note on Monday, February 3rd. BTIG Research set a $403.00 price objective on Stryker and gave the stock a "buy" rating in a research note on Monday, April 14th. Finally, JPMorgan Chase & Co. lifted their price objective on Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $423.53.

Stryker Stock Performance

Shares of SYK traded up $9.21 during trading hours on Wednesday, hitting $357.33. The company had a trading volume of 1,521,368 shares, compared to its average volume of 1,357,140. The firm has a market cap of $136.39 billion, a price-to-earnings ratio of 46.05, a PEG ratio of 2.93 and a beta of 0.93. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The business has a fifty day moving average of $369.25 and a 200-day moving average of $373.06. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the firm earned $3.46 earnings per share. Equities analysts anticipate that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.94%. The ex-dividend date is Monday, March 31st. Stryker's payout ratio is 43.30%.

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the business's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by company insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.